{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:21:43Z","timestamp":1785352903334,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.gore.2023.101290","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:29:03Z","timestamp":1696649343000},"page":"101290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["SJS\/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7984-9692","authenticated-orcid":false,"given":"A.B.","family":"Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Jernigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gore.2023.101290_b0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0022-3859.81865","article-title":"Drug-induced stevens-johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: A multicentric retrospective study","volume":"57","author":"Barvaliya","year":"2011","journal-title":"Journal of Postgraduate Medicine"},{"issue":"4","key":"10.1016\/j.gore.2023.101290_b0010","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: A review article","volume":"29","author":"Chen","year":"2022","journal-title":"Current Oncology"},{"issue":"2","key":"10.1016\/j.gore.2023.101290_b0015","article-title":"Stevens-johnson syndrome in a patient of color: A case report and an assessment of diversity in medical education resources","volume":"14","author":"Diep","year":"2022","journal-title":"Cureus."},{"issue":"2","key":"10.1016\/j.gore.2023.101290_b0020","first-page":"e22245","article-title":"Stevens-johnson syndrome in a patient of color: A case report and an assessment of diversity in medical education resources","volume":"14","author":"Diep","year":"2022","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.gore.2023.101290_b0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management [formula: See text]","volume":"25","author":"Muntyanu","year":"2021","journal-title":"Journal of Cutaneous Medicine and Surgery"},{"issue":"1","key":"10.1016\/j.gore.2023.101290_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.51847\/K833tMZjQP","article-title":"An overview on the evaluation and management of stevens-johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Othman Almadfaa","year":"2022","journal-title":"International Journal of Pharmaceutical Research & Allied Sciences."},{"key":"10.1016\/j.gore.2023.101290_b0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/PPA.S285256","article-title":"Quality of life of drug reaction with eosinophilia and systemic symptom (DRESS) and stevens-johnson syndrome (SJS) and\/or toxic epidermal necrolysis (TEN) patients","volume":"15","author":"Perwitasari","year":"2021","journal-title":"Patient Preference & Adherence."},{"issue":"4","key":"10.1016\/j.gore.2023.101290_b0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/DAD.0000000000001527","article-title":"Pembrolizumab-induced stevens-johnson syndrome\/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: A case report","volume":"42","author":"Robinson","year":"2020","journal-title":"The American Journal of Dermatopathology"},{"issue":"5S","key":"10.1016\/j.gore.2023.101290_b0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN guidelines: Recognition and management of immunotherapy-related toxicity","volume":"16","author":"Thompson","year":"2018","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"5","key":"10.1016\/j.gore.2023.101290_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051237","article-title":"Timeline of adverse events during immune checkpoint inhibitors for advanced melanoma and their impacts on survival","volume":"14","author":"Villa-Crespo","year":"2022","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.gore.2023.101290_b0055","volume":"0","author":"Viscuse","year":"2021","journal-title":"Frontiers in Oncology."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:34Z","timestamp":1762480714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923003077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":11,"alternative-id":["S2352578923003077"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101290","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SJS\/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101290"}}